Showing results (41-50 of 87) with videos related to
Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2009
A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disordersMadeleine Duvic, Sunil A Reddy, Lauren Pinter-Brown, et al.The Journal of Investigative Dermatology|December 30, 2011
Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life toolIvan Grozdev, Douglas Kast, Lauren Cao, et al.Journal of the American Academy of Dermatology|August 19, 2008
Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United StatesSareeta R S Parker, Senait Dyson, Stacey Brisman, et al.Dermatology and Therapy|February 10, 2024
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus PanelJoshua Burshtein, Milaan Shah, Danny Zakria, et al.Journal of the American Academy of Dermatology|March 4, 2008
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screeningAlexa B Kimball, Dafna Gladman, Joel M Gelfand, et al.Journal of the American Academy of Dermatology|October 26, 2017
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week studyLluís Puig, Matthias Augustin, Andrew Blauvelt, et al.Archives of Dermatology|February 21, 2007
National Psoriasis Foundation clinical consensus on disease severityDavid M Pariser, Jerry Bagel, Joel M Gelfand, et al.The Journal of Investigative Dermatology|March 2, 2024
Circulating Monocytes Are Predictive and Responsive in Moderate-to-Severe Plaque Psoriasis Subjects Treated with ApremilastEmma L Larson, Dustin P DeMeo, Andrew B Young, et al.Journal of the American Academy of Dermatology|December 21, 2024
The association between obesity and efficacy of psoriasis therapies: An expert consensus panelJoshua Burshtein, April Armstrong, May Chow, et al.Journal of the American Academy of Dermatology|June 20, 2015
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)Kim Papp, Kristian Reich, Craig L Leonardi, et al.Pageof 9